Migraine Prevention Drugs Demonstrate Net Health Benefit

Source: Institute for Clinical and Economic Review
The Institute for Clinical and Economic Review released a final evidence report on three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine. Panel members voted that evidence was adequate to demonstrate a net health benefit of the CGRP inhibitors for individuals with chronic migraine and no other available treatment options.
Read Final Evidence Report and Report-at-a-Glance

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.

American Academy of Pain Medicine